Taysha Gene Therapies, Inc. (TSHA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.60+0.54%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TSHA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | 9.8 | 8.3 | 15.5 | 2.5 | — | — |
| Total Revenues | — | 9.8 | 8.3 | 15.5 | 2.5 | — | — |
| Operating Expenses & Income | |||||||
| R&D Expenses | 123.1 | 86.4 | 66.0 | 56.8 | 91.2 | 131.9 | 31.9 |
| Operating Income | (153.2) | (110.5) | (91.5) | (72.4) | (162.4) | (173.3) | (43.0) |
| Earnings from Continuing Operations | |||||||
| Interest Expense | — | 0.1 | 0.1 | 5.0 | 3.8 | 1.4 | 0.0 |
| Interest & Investment Income | 11.0 | 9.2 | 6.9 | 3.6 | — | — | — |
| Net Interest Expenses | — | — | — | 1.4 | — | — | — |
| Other Non-Operating Income / Expenses | 3.5 | 1.5 | 2.2 | (39.1) | (3.6) | (1.3) | (17.0) |
| Asset Writedown | — | — | 4.8 | 0.5 | 36.4 | — | — |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | — | 0.0 |
| Net Income | |||||||
| Net Income | (149.6) | (109.0) | (89.3) | (111.6) | (166.0) | (174.5) | (60.0) |
| Per Share | |||||||
| Basic EPS | (0.41) | (0.34) | (0.36) | (0.96) | (3.78) | (4.64) | — |
| Diluted EPS | (0.41) | (0.34) | (0.36) | (0.96) | (3.78) | (4.64) | — |
| Basic Weighted Avg Shares | 369.0 | 319.7 | 250.1 | 116.1 | 44.0 | 37.7 | — |
| Diluted Weighted Avg Shares | 369.0 | 319.7 | 250.1 | 116.1 | 44.0 | 37.7 | — |
| Supplemental | |||||||
| EBIT | (153.2) | (110.5) | (91.5) | (72.4) | (162.4) | (173.3) | (43.0) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.